PENMENVY
Meningococcal Groups A, B, C, W, and Y Vaccine

You are invited to the following presentation:

Topic
Invasive Meningococcal Disease and GSK Vaccine Options

Presented by
JON DVORAK, MD

Date/Time
Tuesday, June 09, 2026
6:00 PM - EST

Location
Rosewood Grill
2033 Crocker Road
Westlake, Ohio 44145

Featuring the personal story of a meningococcal disease patient advocate

RSVP/Questions
EVELYN RODRIGUEZ
evelyn.l.rodriguez@gsk.com
+12165369317

Program code
260609-PEN-119782

Please RSVP by
June 04, 2026

Indication

PENMENVY is a vaccine indicated for active immunization to prevent invasive disease caused by *Neisseria meningitidis* serogroups A, B, C, W, and Y in individuals 10 through 25 years of age.

Important Safety Information for PENMENVY

- Do not administer PENMENVY to individuals with a severe allergic reaction (e.g., anaphylaxis) to a previous dose of PENMENVY, to any component of this vaccine, or to any other diphtheria toxoid-containing vaccine
- Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following the administration of PENMENVY

Please see additional Important Safety Information on the next page, along with the accompanying Prescribing Information for PENMENVY.

Important Safety Information for PENMENVY (Meningococcal Groups A, B, C, W, and Y Vaccine) (cont'd)

- Syncope (fainting) has occurred in association with administration of PENMENVY. Procedures should be in place to avoid injury from fainting
- Vaccination with PENMENVY may not protect all vaccine recipients and may not provide protection against all meningococcal serogroup B strains
- Immunocompromised persons, including those receiving immunosuppressive therapy, may have reduced immune responses to PENMENVY
- Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation are at increased risk for invasive disease caused by *N. meningitidis,* including disease caused by serogroups A, B, C, W, and Y, even if they develop antibodies following vaccination with PENMENVY
- Guillain-Barré syndrome (GBS) has been reported in temporal relationship following administration of a U.S.-licensed meningococcal quadrivalent polysaccharide conjugate vaccine. The decision by the healthcare professional to administer PENMENVY to persons with a history of GBS should take into account the expected benefits and potential risks
- The most commonly reported (≥10%) solicited adverse reactions in individuals aged 10 through 25 years after Dose 1 and Dose 2, respectively, were pain at the injection site (92% and 88%), fatigue (51% and 42%), headache (42% and 36%), myalgia (15% and 12%), nausea (15% and 10%), erythema (13% and 12%), and swelling (13% and 12%). The most commonly reported (≥10%) solicited adverse reactions in MenACWY conjugate vaccine-experienced individuals aged 15 through 25 years after Dose 1 and Dose 2, respectively, were pain at the injection site (80% and 74%), headache (41% and 33%), fatigue (40% and 33%), myalgia (15% and 13%), and nausea (15% and 12%)

Please see additional Important Safety Information on the prior page, along with the accompanying Prescribing Information for PENMENVY.

To register for this program, scan the QR code

Attendance at this promotional program sponsored by GSK is limited to healthcare professionals (HCPs) only. Guests will not be accommodated. Please contact your GSK representative and RSVP by the date above if you would like to attend this program. Some state laws prohibit GSK from providing meals to qualified HCPs. In particular, Vermont state law prohibits GSK from providing meals at this event to HCPs who "regularly practice" in the state of Vermont, or to their employees or agents, even if they primarily practice in another state. Under Vermont law, whether an HCP "regularly practices" in Vermont does not depend on licensure or the amount of time an HCP spends in the state. Rather, it depends on whether an HCP practices in Vermont on some sort of regular basis. For example, if an HCP provides medical services or conducts research 1 week in Vermont every 3 years, that counts as "regularly practice." In addition, many employers (eg, hospitals, teaching institutions, the federal government, and state and local governments) place restrictions on what their employees may accept from outside parties as a condition of employment. GSK respects these restrictions and asks that you limit your participation to those activities permitted by your employer. Note that GSK is publicly disclosing information regarding the monetary value of meals and related expenses provided to you as an attendee at this program.

PENMENVY | GSK
Meningococcal Groups A, B, C, W, and Y Vaccine